Alnylam Pharmaceuticals (ALNY)

May 28, 2025, 8:00 AM EDT - 6 days ago

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

May 20, 2025, 9:00 AM EDT - 14 days ago

Alnylam Issues 2024 Corporate Responsibility Report

May 17, 2025, 5:50 AM EDT - 17 days ago

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

May 12, 2025, 7:00 AM EDT - 22 days ago

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

May 5, 2025, 10:00 AM EDT - 4 weeks ago

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

May 1, 2025, 1:11 PM EDT - 4 weeks ago

Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript

May 1, 2025, 8:00 AM EDT - 4 weeks ago

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

Apr 28, 2025, 8:00 AM EDT - 5 weeks ago

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Apr 17, 2025, 8:00 AM EDT - 6 weeks ago

Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

Apr 1, 2025, 8:00 AM EDT - 2 months ago

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

Mar 31, 2025, 2:05 PM EDT - 2 months ago

Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

XBI RYTM VRTX XENE

Mar 29, 2025, 1:00 PM EDT - 2 months ago

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025

Mar 28, 2025, 4:44 PM EDT - 2 months ago

FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B

Mar 28, 2025, 7:14 AM EDT - 2 months ago

siRNA Gene Silencing Market Landscape Report 2025: United States and Ireland Stand Out with 2 Major M&A Deals Worth $54.9 Billion, Alnylam Pharmaceuticals Leads the Way with 79 Trials

Mar 24, 2025, 2:08 PM EDT - 2 months ago

Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock

Mar 21, 2025, 5:37 PM EDT - 2 months ago

Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster

Mar 21, 2025, 10:00 AM EDT - 2 months ago

Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps

Mar 21, 2025, 7:34 AM EDT - 2 months ago

Alnylam shares rise on expanded heart drug approval

Mar 20, 2025, 5:59 PM EDT - 2 months ago

US FDA approves Alnylam's drug for rare heart condition

Mar 20, 2025, 5:54 PM EDT - 2 months ago

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

Mar 11, 2025, 8:00 AM EDT - 3 months ago

Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum

Mar 5, 2025, 7:00 AM EST - 3 months ago

Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

Feb 25, 2025, 7:00 AM EST - 3 months ago

Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

Feb 13, 2025, 5:01 PM EST - 3 months ago

Alnylam: Waiting For Regulatory Updates In March

Feb 13, 2025, 12:31 PM EST - 3 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 8:00 AM EST - 3 months ago

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress

Jan 30, 2025, 8:00 AM EST - 4 months ago

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results

Jan 12, 2025, 4:00 PM EST - 5 months ago

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals

Jan 7, 2025, 2:43 AM EST - 5 months ago

Alnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025

Jan 6, 2025, 8:00 AM EST - 5 months ago

Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Nov 27, 2024, 7:00 AM EST - 6 months ago

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 7:00 AM EST - 6 months ago

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Nov 17, 2024, 9:30 AM EST - 7 months ago

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

Nov 4, 2024, 8:00 AM EST - 7 months ago

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Oct 31, 2024, 11:26 AM EDT - 7 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 8:00 AM EDT - 7 months ago

Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

Oct 30, 2024, 8:00 AM EDT - 7 months ago

Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024

Oct 27, 2024, 9:00 AM EDT - 7 months ago

Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch

Oct 17, 2024, 8:00 AM EDT - 8 months ago

Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results

Oct 16, 2024, 8:00 AM EDT - 8 months ago

Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Oct 9, 2024, 7:00 AM EDT - 8 months ago

Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

Sep 29, 2024, 9:00 AM EDT - 8 months ago

Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

Sep 26, 2024, 8:00 AM EDT - 8 months ago

Alnylam to Webcast TTR Investor Day

Sep 12, 2024, 7:00 AM EDT - 9 months ago

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly

PFE

Aug 30, 2024, 5:18 PM EDT - 9 months ago

Steward Health Care and Medical Properties Trust Reach Settlement Agreement in Principle, Allowing for Steward-Operated Hospitals to Be Transitioned to New Ownership

Aug 30, 2024, 12:29 PM EDT - 9 months ago

Alnylam: HELIOS-B Success Priced In Already

Aug 30, 2024, 12:06 PM EDT - 9 months ago

Kern Subbasin Groundwater Sustainability Agencies Urge State to Consider Updated Plan

Aug 30, 2024, 9:51 AM EDT - 9 months ago

Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles

Aug 30, 2024, 8:37 AM EDT - 9 months ago

Alnylam shares slide after heart drug data fails to impress investors

Aug 30, 2024, 6:00 AM EDT - 9 months ago

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress